-
Interim NADIM ADJUVANT Data Suggest Adjuvant Chemo-IO May Reduce Recurrence Risk in Patients Following Complete Resection
-
Final FLAURA2 OS Data Show Osimertinib Plus Chemo Offers Benefit Compared with Monotherapy
-
Potential Impact of GLP1-RAs on TKI-induced Weight Gain in Patients with NSCLC
-
No “Known” Risk Factors: The Health Consequences of Radiation Therapy
-
Discussion Covered Updates, Strategies, and Controversies in Lung Cancer Staging
-
No PFS, OS Benefit Seen in Final Results from PACIFIC-2
-
WCLC Attendees Hear Preview of Proposed Changes for the 9th Edition of the TNM Staging Classification for Thoracic Cancers
-
Treatment of Immunotherapy-Related Dermatologic Toxicities: An Interview with Dr. Mario Lacouture
-
A Holistic Approach to Patient Care
screening
-
Balancing the Benefits and Harms of Lung Cancer Screening
In the National Lung Screening Trial, screening with 2 years of annual low-dose computed tomography (LDCT) achieved a 20% decrease in lung cancer mortality in high-risk populations when compared with chest radiography. A decade later, in March 2021, the U.S. Preventive Services Task Force (USPSTF) expanded the eligibility for U.S. adults to ages 50 to…
-
Transbronchial Microwave Ablation of Malignant Lung Nodules: Outcomes, Challenges, and Perspective
With increasing availability of CT scans and strong evidence for the utility of low-dose CT screening in high-risk populations,1 an increasing number of small lung nodules are being incidentally discovered. Many are small, subsolid, and may harbor premalignant or early-stage tumors. Local treatment of early primary lung cancers and lung oligometastases is gaining popularity, especially…
-
Lung Cancer in the Brazilian Health System: Screening, Drug Approvals, Barriers to Care, and Success Stories
By Ricardo Sales dos Santos, MD, PhD, and Juliana Franceschini, PhD Posted: June 24, 2020 Dr. Juliana Franceschini Dr. Ricardo Sales dos Santos The reality of lung cancer in Brazil is as alarming as it is in the rest of the…
-
Disparities in Meeting Eligibility Criteria for Lung Cancer Screening
By Kim L. Sandler, MD, Melinda C. Aldrich, MPH, PhD, and Jeffrey D. Blume, PhD Posted: April 16, 2020 IN REFERENCE TO: Aldrich MC, Mercaldo SF, Sandler KL, Blot WJ, Grogan EL, Blume JD. Evaluation of USPSTF Lung Cancer Screening Guidelines Among African American Adult Smokers. JAMA Oncol. 2019 Jun 27. [Epub ahead of print].…
-
Liquid Biopsy’s Role in Marker Identification: An Interview With Dr. Martin Filipits
Posted: April 16, 2020 As we know, molecular marker identification allows for more rational use of existing therapies. When markers can be identified more effectively and quickly, patient care advances. In the following interview, Martin Filipits, PhD, discusses liquid biopsy’s role in marker identification and the downstream effects of its use. Dr. Filipits is a…